Astellas Pharma Shares Outstanding 2012-2025 | ALPMY

Astellas Pharma shares outstanding history from 2012 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Astellas Pharma shares outstanding for the quarter ending December 31, 2025 were 0M, a 100% decline year-over-year.
Astellas Pharma 2025 shares outstanding were 1.797B, a 0.16% decline from 2024.
Astellas Pharma 2024 shares outstanding were 1.8B, a 1.39% decline from 2023.
Astellas Pharma 2023 shares outstanding were 1.825B, a 1.38% decline from 2022.

Astellas Pharma Annual Shares Outstanding (Millions of Shares)
2025	1,797
2024	1,800
2023	1,825
2022	1,851
2021	1,858
2020	1,878
2019	1,934
2018	2,032
2017	2,123
2016	2,161
2015	2,212
2014	2,247
2013	2,294
2012	2,340

Astellas Pharma Quarterly Shares Outstanding (Millions of Shares)
2025-12-31
2025-09-30
2025-06-30	1,795
2024-06-30	1,796
2023-06-30	1,795
2022-06-30	1,826
2021-06-30	1,854
2020-06-30	1,859
2019-06-30	1,888
2018-06-30	2,008
2017-06-30	2,066
2016-09-30	2,160
2016-06-30	2,127
2016-03-31	2,161
2015-12-31	2,170
2015-09-30	2,179
2015-06-30	2,190
2015-03-31	2,212
2014-12-31	2,216
2014-09-30	2,217
2014-06-30	2,223
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31

Sector	Industry	Market Cap	Revenue
Medical	Medical - Drug Manufacturing	$29.805B	$12.558B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.

Stock Name	Country	Market Cap	PE Ratio
Chugai Pharmaceutical (CHGCY)	Japan	$89.845B	31.38
UCB SA (UCBJY)	Belgium	$60.713B	0.00
Takeda Pharmaceutical (TAK)	Japan	$57.538B	11.30
Zoetis (ZTS)	United States	$49.577B	18.36
Sandoz Group AG (SDZNY)	Switzerland	$37.136B	0.00
Otsuka Holdings, - (OTSKY)	Japan	$36.393B	14.73
BeOne Medicines - (ONC)	Switzerland	$33.976B	83.02
Daiichi Sankyo, - (DSNKY)	Japan	$33.284B	16.12
United Therapeutics (UTHR)	United States	$25.058B	20.49
Shionogi (SGIOY)	Japan	$18.069B	13.97
Merck (MKKGY)	Germany	$16.944B	11.65
IPSEN (IPSEY)	France	$16.273B	0.00
Summit Therapeutics (SMMT)	United States	$15.264B	0.00
Neurocrine Biosciences (NBIX)	United States	$12.936B	27.96
Ionis Pharmaceuticals (IONS)	United States	$12.417B	0.00
Madrigal Pharmaceuticals (MDGL)	United States	$11.920B	0.00
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF)	Italy	$11.749B	16.23
Orion OYJ (ORINY)	Finland	$10.723B	18.62
Eisai (ESAIY)		$9.158B	0.00
Ono Pharmaceutical (OPHLF)	Japan	$6.834B	16.35
Centessa Pharmaceuticals (CNTA)	United Kingdom	$6.102B	0.00
Grifols, S.A (GRFS)	Spain	$5.588B	0.00
Corcept Therapeutics (CORT)	United States	$4.458B	51.11
Crinetics Pharmaceuticals (CRNX)	United States	$4.130B	0.00
Stevanato Group S.p.A (STVN)	Italy	$4.094B	22.53
NewAmsterdam Pharma (NAMS)	Netherlands	$3.997B	0.00
AMNEAL PHARMACEUTICALS, INC (AMRX)	United States	$3.945B	16.50
Hikma Pharmaceuticals Plc (HKMPF)	United Kingdom	$3.838B	0.00
Indivior Pharmaceuticals (INDV)	United States	$3.724B	12.41
Hypermarcas (HYPMY)	Brazil	$3.308B	13.82
Dyne Therapeutics (DYN)	United States	$3.086B	0.00
Catalyst Pharmaceuticals (CPRX)	United States	$3.046B	9.86
Oruka Therapeutics (ORKA)	United States	$2.952B	0.00
Soleno Therapeutics (SLNO)	United States	$2.717B	228.83
Enliven Therapeutics (ELVN)	United States	$2.710B	0.00
Relay Therapeutics (RLAY)	United States	$2.670B	0.00
Guardian Pharmacy Services (GRDN)	United States	$2.479B	41.65
BioCryst Pharmaceuticals (BCRX)	United States	$2.398B	7.19
Nektar Therapeutics (NKTR)	United States	$2.223B	0.00
Definium Therapeutics (DFTX)	United States	$2.147B	0.00
Avadel Pharmaceuticals (AVDL)	Ireland	$2.113B	0.00
Aurinia Pharmaceuticals Inc (AUPH)	Canada	$2.096B	19.46
Ocular Therapeutix (OCUL)	United States	$1.914B	0.00
Amylyx Pharmaceuticals (AMLX)	United States	$1.808B	0.00
Ardelyx (ARDX)	United States	$1.516B	0.00
Harrow (HROW)	United States	$1.338B	79.84
Savara (SVRA)	United States	$1.158B	0.00
Collegium Pharmaceutical (COLL)	United States	$1.149B	5.37
Xeris Biopharma Holdings (XERS)	United States	$1.009B	0.00
KalVista Pharmaceuticals (KALV)	United States	$0.993B	0.00
Cronos Group (CRON)	Canada	$0.971B	0.00
Evotec AG (EVO)	Germany	$0.935B	0.00
Xencor (XNCR)	United States	$0.911B	0.00
Aktis Oncology (AKTS)	United States	$0.901B	0.00
Theravance Biopharma (TBPH)	United States	$0.842B	21.80
ARS Pharmaceuticals (SPRY)	United States	$0.799B	0.00
Relmada Therapeutics (RLMD)	United States	$0.765B	0.00
Bioventus (BVS)	United States	$0.753B	13.32
Ironwood Pharmaceuticals (IRWD)	United States	$0.592B	15.78
ProKidney (PROK)	United States	$0.589B	0.00
Esperion Therapeutics (ESPR)	United States	$0.557B	0.00
Zevra Therapeutics (ZVRA)	United States	$0.556B	9.19
Rigel Pharmaceuticals (RIGL)	United States	$0.540B	4.49
Lyell Immunopharma (LYEL)	United States	$0.522B	0.00
Larimar Therapeutics (LRMR)	United States	$0.504B	0.00
4D Molecular Therapeutics (FDMT)	United States	$0.501B	0.00
Aquestive Therapeutics (AQST)	United States	$0.498B	0.00
Aclaris Therapeutics (ACRS)	United States	$0.487B	0.00
Nature's Sunshine Products (NATR)	United States	$0.471B	21.37
Lexeo Therapeutics (LXEO)	United States	$0.443B	0.00
Altimmune (ALT)	United States	$0.422B	0.00
Elite Pharmaceuticals (ELTP)	United States	$0.409B	37.99
Century Therapeutics (IPSC)	United States	$0.404B	0.00
Akebia Therapeutics (AKBA)	United States	$0.375B	0.00
USANA Health Sciences (USNA)	United States	$0.334B	9.43
AleAnna (ANNA)	United States	$0.333B	124.75
Surrozen (SRZN)	United States	$0.324B	0.00
Siga Technologies (SIGA)	United States	$0.312B	14.06
Avalo Therapeutics (AVTX)	United States	$0.311B	0.00
Organogenesis (ORGO)	United States	$0.306B	8.81
Silence Therapeutics (SLN)	United Kingdom	$0.271B	0.00
Cybin (HELP)	Canada	$0.270B	0.00
Protara Therapeutics (TARA)	United States	$0.268B	0.00
Prelude Therapeutics (PRLD)	United States	$0.257B	0.00
Minerva Neurosciences (NERV)	United States	$0.238B	0.00
Procaps Group, S.A (PROCF)	Luxembourg	$0.230B	0.00
MediWound (MDWD)	Israel	$0.229B	0.00
Context Therapeutics (CNTX)	United States	$0.229B	0.00
Enlivex (ENLV)	Israel	$0.228B	0.00
Inhibikase Therapeutics (IKT)	United States	$0.224B	0.00
Profound Medical (PROF)	Canada	$0.216B	0.00
OmniAb (OABI)	United States	$0.213B	0.00
Achieve Life Sciences (ACHV)	Canada	$0.186B	0.00
Korro Bio (KRRO)	United States	$0.183B	0.00
Corbus Pharmaceuticals Holdings (CRBP)	United States	$0.174B	0.00
Unicycive Therapeutics (UNCY)	United States	$0.167B	0.00
Tonix Pharmaceuticals Holding (TNXP)	United States	$0.167B	0.00
Heron Therapeutics (HRTX)	United States	$0.161B	0.00
Cardiol Therapeutics (CRDL)	Canada	$0.154B	0.00
Avita Medical (RCEL)	United States	$0.154B	0.00
VAXART, INC (VXRT)	United States	$0.152B	10.50
Galectin Therapeutics (GALT)	United States	$0.151B	0.00
Karyopharm Therapeutics (KPTI)	United States	$0.147B	0.00
Journey Medical (DERM)	United States	$0.141B	0.00
Assertio Holdings (ASRT)	United States	$0.116B	0.00
Innate Pharma SA (IPHYF)	France	$0.115B	0.00
Aldeyra Therapeutics (ALDX)	United States	$0.107B	0.00
Pyxis Oncology (PYXS)	United States	$0.107B	0.00
Cassava Sciences (SAVA)	United States	$0.101B	0.00
Vivani Medical (VANI)	United States	$0.088B	0.00
Verrica Pharmaceuticals (VRCA)	United States	$0.088B	0.00
PolyPid (PYPD)	Israel	$0.082B	0.00
Nuo Therapeutics (AURX)		$0.082B	0.00
Champions Oncology (CSBR)	United States	$0.080B	0.00
Gain Therapeutics (GANX)	United States	$0.076B	0.00
NRx Pharmaceuticals (NRXP)	United States	$0.073B	0.00
Fractyl Health (GUTS)	United States	$0.073B	0.00
PMV Pharmaceuticals (PMVP)	United States	$0.070B	0.00
Rafael Holdings (RFL)	United States	$0.066B	0.00
Dominari Holdings (DOMH)	United States	$0.065B	0.00
Acrivon Therapeutics (ACRV)	United States	$0.060B	0.00
ElectroCore (ECOR)	United States	$0.049B	0.00
Nutriband (NTRB)	United States	$0.047B	0.00
Cumberland Pharmaceuticals (CPIX)	United States	$0.046B	34.33
SCYNEXIS (SCYX)	United States	$0.045B	0.00
Lite Strategy (LITS)	United States	$0.042B	0.00
Telomir Pharmaceuticals (TELO)	United States	$0.042B	0.00
FibroGen (FGEN)	United States	$0.039B	0.00
Talphera (TLPH)	United States	$0.038B	0.00
Incannex Healthcare (IXHL)	Australia	$0.037B	0.00
Mural Oncology (MURA)	Ireland	$0.035B	0.00
Plus Therapeutics (PSTV)	United States	$0.033B	0.00
Tempest Therapeutics (TPST)	United States	$0.029B	0.00
MARKER THERAPEUTICS, INC (MRKR)	United States	$0.029B	0.00
TherapeuticsMD (TXMD)	United States	$0.024B	0.00
VYNE Therapeutics (VYNE)	United States	$0.020B	0.00
Citius Pharmaceuticals (CTXR)	United States	$0.018B	0.00
Natural Alternatives (NAII)	United States	$0.018B	0.00
Klotho Neurosciences (KLTO)	United States	$0.016B	0.00
Lipocine (LPCN)	United States	$0.016B	0.00
Vyome Holdings (HIND)	United States	$0.015B	0.00
Iterum Therapeutics (ITRM)	Ireland	$0.015B	0.00
Jupiter Neurosciences (JUNS)	United States	$0.014B	0.00
Wellgistics Health (WGRX)	United States	$0.014B	0.00
Phio Pharmaceuticals (PHIO)	United States	$0.014B	0.00
Scienture Holdings (SCNX)	United States	$0.014B	0.00
Curanex Pharmaceuticals Inc (CURX)	United States	$0.013B	0.00
Vivos Therapeutics (VVOS)	United States	$0.013B	0.00
Traws Pharma (TRAW)	United States	$0.012B	0.02
Ainos (AIMD)	United States	$0.012B	0.00
Cosmos Health (COSM)	United States	$0.011B	0.00
Mannatech (MTEX)	United States	$0.011B	0.00
Quoin Pharmaceuticals (QNRX)	United States	$0.011B	0.00
CASI Pharmaceuticals (CASI)	China	$0.010B	0.00
BioVie (BIVI)	United States	$0.010B	0.00
BioLineRx (BLRX)	Israel	$0.010B	0.00
Reviva Pharmaceuticals Holdings (RVPH)	United States	$0.010B	0.00
Kiora Pharmaceuticals (KPRX)	United States	$0.010B	0.00
Liminatus Pharma (LIMN)	United States	$0.008B	0.00
Addex Therapeutics (ADXN)	Switzerland	$0.008B	0.00
Inotiv (NOTV)	United States	$0.008B	0.00
TransCode Therapeutics (RNAZ)	United States	$0.008B	0.00
Heatwurx (PCSA)	United States	$0.007B	0.00
Nuvilex (PMCB)	United States	$0.007B	0.00
Xenetic Biosciences (XBIO)	United States	$0.007B	0.00
Alaunos Therapeutics (TCRT)	United States	$0.007B	0.00
Biomerica (BMRA)	United States	$0.006B	0.00
Aptorum Group (APM)	United Kingdom	$0.006B	0.00
Mangoceuticals (MGRX)	United States	$0.006B	0.00
Ernexa Therapeutics (ERNA)	United States	$0.006B	0.00
XTL Biopharmaceuticals (XTLB)	Israel	$0.005B	0.00
Salarius Pharmaceuticals (SLRX)	United States	$0.005B	0.00
Indaptus Therapeutics (INDP)	United States	$0.005B	0.00
60 Degrees Pharmaceuticals (SXTP)	United States	$0.005B	0.00
Redhill Biopharma (RDHL)	Israel	$0.004B	0.00
Galmed Pharmaceuticals (GLMD)	Israel	$0.004B	0.00
Sonoma Pharmaceuticals (SNOA)	United States	$0.004B	0.00
Shuttle Pharmaceuticals Holdings (SHPH)	United States	$0.004B	0.00
XORTX Therapeutics (XRTX)	Canada	$0.003B	0.00
InMed Pharmaceuticals (INM)	Canada	$0.002B	0.00
China SXT Pharmaceuticals (SXTC)	China	$0.002B	0.00
Clearmind Medicine (CMND)	Canada	$0.002B	0.00
Universe Pharmaceuticals INC (UPC)	China	$0.002B	0.00
Jaguar Animal Health (JAGX)	United States	$0.001B	0.00
SciSparc (SPRC)	Israel	$0.001B	0.00
PainReform (PRFX)	Israel	$0.001B	0.00
Aditxt (ADTX)	United States	$0.000B	0.00
CDT Equity (CDT)	United States	$0.000B	0.00
Emisphere Technologies (EMIS)	United States	$0.000B	0.00
4D Pharma (LBPS)	United Kingdom	$0.000B	0.00
Patheon (PTHN)	Netherlands	$0.000B	0.00
RVL Pharmaceuticals (RVLP)	United States	$0.000B	0.00